US Biologicals partnered with Glycoselect to bring RPL lectins to life science researchers

US Biological to bring GlycoSeLect RPL lectins to life science researchers

GlycoSeLect Ltd is delighted to announce that its innovative recombinant prokaryotic lectins, RPLs for glycoprotein separation, characterisation and analysis are now available from United States Biological. The Salem, Mass. based company is a primary brand for the Life Science industry and a go-to supplier for value, integrity and customer service.

GlycoSeLect’s CEO Robert Dunne said that “US Biological is an ideal partner to bring RPL lectins to glycoprotein researchers across the life science industry. Our RPL products have a focus on value by reducing the cost of analyses, and we like to help our customers with their separation and analytical challenges”

US Biological CEO Warren Shore stated that “Lectins are incredibly useful specialty proteins that have applications throughout Biotechnology. There has previously been a scarcity of strong supply and support, and we are incredibly excited to partner with GlycoSeLect to bring their new products to existing markets as well as develop new applications. United States Biological can immediately offer these new Lectins throughout our marketing channels of more than 100 distributors in most countries”.

About GlycoSelect Ltd

GlycoSeLect Ltd is an early-stage biotechnology company developing proprietary innovative and cost-efficient solutions for the analysis, characterisation and purification of pharmaceutical products. Spun-out from Dublin City University in 2013, GlycoSeLect specialises in the development of RPLs; proteins that enable the more efficient detection, analysis and selective isolation of glycosylated biomolecules. GlycoSeLect established a UK based subsidiary in 2015 to support further development, provide wider geographic reach and drive commercialisation.

More Stories